![]() | ![]() |
Formats:
|
||||||||||||||||
Copyright © 2006 by The National Academy of Sciences of the USA Biochemistry Semirational design of Jun-Fos coiled coils with increased affinity: Universal implications for leucine zipper prediction and design Institut für Biologie III, Universität Freiburg, Schänzlestrasse 1, D-79104 Freiburg, Germany *To whom correspondence should be addressed. E-mail: katja/at/biologie.uni-freiburg.de Edited by Jennifer A. Doudna, University of California, Berkeley, CA, and approved April 18, 2006 Author contributions: J.M.M. and K.M.A. designed research; J.M.M. performed research; M.A.S., K.M.M., and K.M.A. contributed new reagents/analytic tools; J.M.M., M.A.S., K.M.M., and K.M.A. analyzed data; and J.M.M. and K.M.A. wrote the paper. Received November 14, 2005. This article has been cited by other articles in PMC.Abstract Activator protein-1 (AP-1) is a crucial transcription factor implicated in numerous cancers. For this reason, nine homologues of the AP-1 leucine zipper region have been characterized: Fos (c-Fos, FosB, Fra1, and Fra2), Jun (c-Jun, JunB, and JunD), and semirational library-designed winning peptides FosW and JunW. The latter two were designed to specifically target c-Fos or c-Jun. They have been identified by using protein-fragment complementation assays combined with growth competition. This assay removes nonspecific, unstable, and protease susceptible library members from the pool, leaving winners with excellent drug potential. Thermal melts of all 45 possible dimeric interactions have been surveyed, with the FosW–c-Jun complex displaying a melting temperature (Tm) of 63°C, compared to only 16°C for wild-type c-Fos–c-Jun interaction. This impressive 70,000-fold KD decrease is largely due to optimized core packing, α-helical propensity, and electrostatics. Contrastingly, due to a poor c-Fos core, c-Fos–JunW dimerizes with lower affinity. However the Tm far exceeds wild-type c-Fos–c-Jun and averaged JunW and c-Fos, indicating a preference over either homodimer. Finally, and with wider implications, we have compiled a method for predicting interaction of parallel, dimeric coiled coils, using our Tm data as a training set, and applying it to 59 bZIP proteins previously reported. Our algorithm, unlike others to date, accounts for helix propensity, which is found to be integral in coiled coil stability. Indeed, in applying the algorithm to these 592 bZIP interactions, we were able to correctly identify 92% of all strong interactions and 92% of all noninteracting pairs. Keywords: bioinformatics, protein design, protein stability, protein–protein interaction, dominant negative The dimeric transcription factor activator protein-1 (AP-1) comprises Jun, Fos, activating transcription factor, and musculoaponeurotic fibrosarcoma families. Chief mammalian cell AP-1 constituents, Jun and Fos, contain a transactivation domain, a basic region for recognizing a DNA consensus sequence and a leucine zipper [coiled coil (CC)] region (see Fig. 1
Found within 3–5% of all encoded amino acids (3), CCs are, despite their versatility, highly specific. In bZIP proteins, the CC consists of two parallel α-helices that wrap around one another in a left-handed supercoil. Characterized by a repeat of seven amino acids, denoted a-g, residues a and d consist largely of hydrophobic residues, forming a stripe which associates with respective partners on the other helix. Core flanking charged residues at e and g positions form interhelical ion pairs with g′ and e′ residues in the neighboring helix. Core region proximity means these residues are partially shielded from the solvent (4). For recent reviews of CC structures in general see refs. 5–7. In this work, we describe the generation of high-affinity peptides able to bind their intended target (with higher affinity than wild-type). The beauty of this semirational approach lies in adding both intuitive and unintuitive library members, from which truly unique inhibitor sequences can arise. The possibility of broader interpretations has led us to include data sets taken from homologue variations. Diverse changes permit more universal conclusions, whereas differences in binding strengths and stabilities can also permit an understanding of how partners constituting AP-1 exert their effects. This simplification [differences in DNA binding domains, modifications (such as phosphorylation), and concentrations in vivo also play major roles] provides useful information regarding CC roles in conferring stability and specificity. Despite this, understanding CC contribution to stability should paint a clearer picture in the tumorigenic prevalence of particular AP-1 pairings. Fos and Jun family based libraries have been designed with optimized residues crucial for dimerization and stability using numerous potential residues options (including most wild-type residues). Importantly, unintuitive residue selections, arising from retained wild-type amino acids and those appearing to contribute poorly to overall stability (from homologues), were included as well. Often far from the core, these can fulfill poorly understood roles in intramolecular interactions, helical propensity, and solubility, generating improved overall stability. Interacting helices from gene libraries were assayed by using a protein-fragment complementation assay (8, 9), generating soluble, nonaggregating, protease-resistant, stable inhibitors, binding their targets with maximum efficacy. Sequestering one half of AP-1 with such potency should strongly and indefinitely inhibit transcription of the target gene. Changes in the helix sequences will also consent improved understanding of CC stability, progressing beyond “Peptide Velcro” simplicity (10, 11). Results Targeting c-Fos: Design of Jun Library and Selection of JunW. Despite being a reasonable CC, with good core and electrostatic properties, the Jun interaction pattern with Fos is still taxing to understand. Consequently, in library design, wild-type core a residues have been retained, with similar options introduced (Fig. 1 The N–K a3 pair observed in the Jun-Fos heterodimer was kept, along with I and K options in the library. Despite instability incurred from N–N and K–K pairings, hydrogen bonding plays a role in specificity determination (15). This has been disputed on the grounds that both a–g′ (parallel) and a–e′ (antiparallel) K–E interactions can occur, with K side chain internal methylene groups maintaining core integrity (16). Additionally, K–I pairs are stable compared to N–K, although specificity conferred by such pairings are unknown. Regardless, the option is a good test-bed within our experimental confines, as either c-Fos–c-Fos or JunW–JunW homodimers forming preferentially over c-Fos–JunW will slow bacterial growth and be removed from the pool. Interestingly, in the selection process N and K (opposite c-Fos K) were rejected from a3 in favor of I. In parallel dimeric CCs, a gi residue can form a coulombic interaction with an e′i+1 residue of the next heptad on the opposite helix (6). In the JunW, the e3 position was changed from A to Q with both R and K rejected (Fig. 1 Positions g1, g2, and a2, settled fastest, and are perhaps pertinent in heterodimer formation or stability. g1 R was predicted to pair well with c-Fos e2 E while shielding the core better than alternatives Q or K. Both a1 and a4 fluctuated between V and A, with the latter selected last, suggesting no major preference between these residues at this position. Targeting c-Jun: Fos Library Design and Selection of FosW. In core design, Fos has much scope for improvement comparative to Jun. Consequently, FosW–c-Jun will always be more stable than a corresponding JunW–c-Fos. The instability of c-Fos (it cannot homodimerize) is the principal heterodimeric driving force for c-Jun–c-Fos formation, rather than heterodimeric preference over c-Jun–c-Jun homodimers (18). Repulsive g/e′ interactions and poor core a residues largely explain this phenomenon (Fig. 1 g/e′i+1 interacting pairs, which complement c-Jun, were introduced according to Vinson’s free energy values (17). g1 and e2 E residues, conserved in Fos homologues, were proposed to be central in accounting for most additional heterodimerization free energy with c-Jun (22), and were not varied in the library. Variations from Fos homologues were included in library design. In winning e and g positions, no wild-type residues were selected. Other options such as e3 R were reasoned to form g/e′i+1 interactions with g2 Q of c-Jun. Some changes (all from homologue variations, see Fig. 1 I at a4 settled fastest from all positions and could be the most extended option for packing against a small c-Jun a4 A side chain, with V too short, and L’s extra steric bulk less favored. Thermal Melts of Winner and Homologues. CD spectrums revealed all dimers to be α-helical (data not shown), whereas 45 helical melts (Figs. 2
Rationalization by Core, Electrostatic, and Propensity Ranking. Relating stability changes to peptide combinations is a daunting task involving a plethora of factors. Core changes affect hydrophobic burial, propensity, solubility, electrostatic attraction of flanking residues, and a number of intramolecular interactions. Ranking contributions, and building a relationship between residue changes and Tm, is consequently very difficult. However, three overriding factors (core, electrostatic and propensity) have been considered. Accordingly, we have devised an improved algorithm for CC prediction using core, electrostatic, as well as propensity. This algorithm can be found online at www.molbiotech.uni-freiburg.de/bCIPA and is known as the bZIP coiled coil interaction prediction algorithm (bCPIPA). A rudimentary core packing score has been assigned to all dimers to distinguish cores which make large contributions to stability from those which do not (Fig. 3 Our electrostatic parameters are based on opposing charge pairings and place energetic penalties on similar charge pairings (DD≈DE≈EE≈RR≈KK≈RK = +1; KD≈RD≈EQ = −0.5; KQ≈RQ = −1; QQ≈KE≈RE = −1.5) with gi/e′i+1 and ei+1/gi′ interactions treated the same for simplicity. Electrostatic interactions were related to free energy contributions based on data from a double mutant analysis (17). Consequently, although not included implicitly in the study, the scale indicates much improved electrostatic attractions. Fong et al. (24) used “base optimized weighting” to predict CC interactions, and identified strong interactions based on did′i, aia′i, aid′i, dia′i+1 die′i, gia′i+1, and gie′i+1 pairings (24), but did not consider α-helical stability as a direct contributing factor. However, we estimate helical propensity to be hugely important and a largely overlooked third parameter in CC stability (covered in depth in Discussion), precluding electrostatic and core considerations in forming a structure which is in a dimerization competent state. Surprisingly, we find that only two of the seven considerations made by Fong et al. (24) are strictly necessary (ad′, da′, de′, ga′ pairings are not required, and aa′ and dd′ count as one), and that propensity is a more important omission. Indeed, the role of surface residues has been probed for GCN4-p1, with helix propensity found to be a key factor in surface design (25). Additionally, intramolecular hydrogen bonding of high propensity residues such as Q, R, E, or K, which frequent these positions is also important, and if unsatisfied, can cause unfavorable effects. In combining these parameters with a least squares fit, stability can be rationalized and agrees well with actual Tm values (Fig. 4
In our fitting procedure, core pairings (d/d′ = a/a′), g/e′ electrostatic preferences and propensity scales from Williams et al. (26) were used to fit our Tm data (45 dimers) as well as selected and rationally designed peptides characterized previously (12 dimers) (9, 11). A least squares fit to these 57 dimers (see Eq. 2) yielded the coefficients a1 = 189.8, a2 = −11.8, a3 = −4.3, d = −299.6. The difference in magnitude results from the different scales used to score helix propensity, core, and electrostatics. Considering these, all three terms lie in the same range (see also supporting information). Our fit (www.molbiotech.uni-freiburg.de/bCIPA) yielded an r2 of 0.74 (Fig. 4 Having obtained these fits, 592 bZIP interactions (which contained none of the data within our training set) probed in a microarray analysis by Newman and Keating (27) were used to test the ability of our algorithm in correctly predicting strong and noninteractions. Using similar criteria as described by Fong et al. (24), we were able to correctly identify 92% of noninteractors and 92% of strong interactors, although only e/g, a/a, and d/d pairings and very basic weightings scales were used. Predictions by Fong et al. (24) reported similar values of 89% and 83%. Discussion Screening of in vivo peptide libraries, as well as binding studies to elucidate affinity for homologues, has given valuable insight into the mechanism of CC stability. Ranking the affinities of all possible AP-1 homologue pairings may also be relevant in the preponderance of oncogenic pairings in vivo. Dominant Negatives (DN) Directed Against AP-1. The concept of DN to compete with wild-type bZIP or helix–loop–helix bZIP (HLH–bZIP) is not new. A peptide previously designed to bind the c-Jun CC, preventing functional c-Jun–c-Fos and c-Jun–c-Jun, had been constructed (14). Acidic, E-rich extended CCs, designed as DNA mimics, were able to bind and even sequester DNA bound AP-1 (28), a task requiring impressive KD values in the pM range. A c-Jun transactivation domain deletion mutant, TAM67, is able to arrest AP-1 activity in normal and malignant breast cells (29). Further elucidation of rules governing CC stability and specificity will aid in potential drug development. Stability of AP-1. AP-1 Tm variations depend on numerous factors. Previous experiments have been disulfide bridged (30, 31), had basic domains (28), been of varying length (27), and been conducted under various conditions (ionic strength, pH, etc.). Boysen et al. (30) 38-residue bridged CCs display Tms of 59, 69, and 71°C for c-Fos–c-Fos, c-Jun–c-Jun, and c-Fos–c-Jun, respectively. Olive et al. (28) report 25, 30, and 50°C, for the same complexes unbridged but with acidic extensions, whereas O’Shea et al.’s (31) bridged peptides have Tms of 30, 41, and 51°C. There are only some early qualitative studies that document existence of alternative Jun–Fos homologue dimers beyond c-Jun–c-Fos (32–36). In the only comprehensive, semiquantitative, study to date (27), Jun–Fos homologues range from 84–107 residues, contain terminal subcloning sequences, a his-tag, an N-terminal basic region extension, and at least nine residues of C-terminal extension until the paircoil program (37) predicts the probability of CC to be <10%. In contrast, our peptides are all 37-mers of same register from the CC region, N- and C-capped, and are not disulfide bridged. Despite these differences, the core CC sequences (excepting a b position Y for absorbance) are identical in both studies, and display moderate agreement with our own Tm values. Using Z scoring (27) as an affinity measure, that earlier study showed in a microarray analysis heterodimers to yield a good interaction (Z > 10). Homodimeric Fos typically displayed low stabilities, and homodimeric Jun combinations (excepting c-Jun; Z > 5, Tm 40°C) were less stable than heterodimers. We found c-Jun–c-Jun to be more stable than c-Jun–c-Fos; however, our data do not dispute that c-Fos instability drives heterodimeric preference (18). Regardless, excluding electrostatic considerations, c-Jun–c-Jun has better α-helical propensity, and a significantly more stable core than c-Fos–c-Jun. Importantly, to our knowledge, our study is the first quantitative biochemical analysis of all possible Jun-Fos CC combinations from human (see Fig. 3 Core Conclusions from Winners. Core comparison indicates that dimeric Fos homologue cores are disfavored compared to Fos–Jun, with Jun cores displaying greater hydrophobic burial and greater stability. Winners have similar (JunW) or enhanced (FosW) cores compared to homologues, resulting in optimized cores and improved stabilities. In general, I is favored over V in winner a positions, has higher propensity, and is bulkier for core packing. It has been reported to be more stable and better than V and L at this position in conferring dimers (12, 13). FosW L and I were selected over V in all four instances, despite a documented β- over γ-branching preference (12, 38). V alone yields trimers (39) or a mixture of dimers and trimers (12), whereas I can specify dimers exclusively. Surprisingly, no homotypic pairing preference was observed in FosW–c-Jun, with aa′ LI, IV, IA, and LV selected. Nor were any a1 or a2 TT pairings observed despite speculation that generally homotypic pairings are energetically favored over similar hydrophobic pairings (23). In contrast, the bulk of core winner aa′ pairings are heterotypic. g/e′i+1 Conclusions from Winners. Abundance of strong interacting pairs involving (with the exception of Q) terminal charge attractions such as KE, RE, QE, QQ, RQ, and KQ, suggest that hydrophobic bulk plays an additional role (40, 41). The side chain of E (−(CH2)2COO−) can pair with K (−(CH2)4–NH3+) and R (−(CH2)3–NH–C(NH)(NH3+)) side chains, both having positively charged termini able to contact the negative carboxyl group of E. Q is also favorable, possibly because its side chain (−(CH2)2CONH2) is of sufficient length to shield the core from the solvent. However, lack of terminal charge is predicted to lower the specificity of the interaction. Partial hydrophobic environment felt by the side chains may also improve the energetic contribution of these charge interactions, yielding a greater contribution in less aqueous surroundings. However, from frequency in CCs (40, 41) and energetic rankings (17), we conclude that D and N (both of which are shorter, containing only one side chain methylene group) are disfavored and should be omitted in designed coils, despite possible charge complementarity (for D) with K or R again due to poor core shielding. The extra length and polarity of the JunW e3 A → Q change is likely to enable contact with the corresponding E at c-Fos g2. Additionally, the extra hydrophobic bulk of Q’s β- and γ-carbon methylene groups can stabilize the molecule by shielding the core from the solvent to a greater extent than can A (4), and these methylene groups may provide favorable interactions with the d3 δ-carbon methylene groups of c-Fos L. Electrostatic attractions estimated according to Krylov et al. (17) in c-Fos–JunW (ΔΔG = −5.2 kcal/mol), are improved compared to the c-Fos homodimer (−0.6 kcal/mol) and surpass the average of c-Fos and JunW homodimers (−2.4 kcal/mol), indicating an electrostatic preference for heterodimer formation. Outer Positions: Intrahelical Stability and Solubility. Incorporating Fos homologue residue changes at solvent exposed regions interestingly resulted in acceptance of all proposed amino acids at all nine positions in the library winner (Fig. 1 Helical Propensity Considerations. Propensity scales inform upon the frequency or preference with which a given residue occurs in a particular conformation. In our analysis we have used the scales devised by Williams et al. (26) as well as Gromiha and Parry (42). From these scales, averaged helical propensity predictions were assigned to each of the helices, discounting N- and C-caps. Williams et al. is similar to the Chou and Fasman scale (43) in that it is derived from statistical data, whereas Gromiha and Parrys is derived specifically from CCs, with the former scale giving a mildly better fit to our data set. We favored these scales over other experimental approaches (44–46) because they include not only substituted solvent exposed residues at the center of a helix, but partially and completely buried residues together with residues at the helix termini, both of which would differ in propensity in these contexts (47, 48). This finding is of particular significance in short helical CC motifs such as ours, where residues are completely buried, partially buried, or completely solvent exposed, depending on side chain and heptad position, or centrally or terminally located. Analysis of the homologues predicts winning peptides will display increased helicity. This is somewhat surprising given that it was not a criterion in library design. However, homologues are informative in this respect because they contain higher proportions of the destabilizing residue G and S compared to c-Jun and c-Fos, which is also reflected in their poor homodimeric and heterodimeric Tm values. Although G is universally accepted as a poor helical propensity residue, S is more contentious, but may account for improvement in fit to our data set when using the scale of Williams et al. (26). G is particularly destabilizing due to increased numbers of and ψ angles accessible to the backbone. This destabilization results in an unfavorable conformational entropy change upon helix formation. S may display poor helical propensity (26, 43) because its side chain hydroxyl donor competes for an interaction with the surrounding backbone NH and CO groups. Consistent with both helical scales used here is a similar scenario with acceptor groups at the terminus of N and D side chains. In designed helices, these residues should be avoided in favor of the longer Q (or E), which are also likely to display greater conformational entropy in the unfolded state than S, D, or N (48). Likewise, the role of electrostatic preferences clearly reaches beyond charge pairing preferences. Propensity predicts R, Q, E, and K (α-helical propensity PαR = 1.21, PαQ = 1.27, PαE = 1.59, PαK = 1.23), being favored, with both D and N (PαD = 0.99, PαN = 0.76) disfavored (26) (see also refs. 42–44). Pace and Scholtz (48) suggest that polar groups separated from the backbone by one methylene group (e.g., D) have a lower propensity than those with two (e.g., E) due to the cost of fixing an extra methylene group in random-coil state, thus favoring helix formation.α-Helical propensity in the JunW core plays a key role additional to hydrophobic burial in selecting winning amino acids. Of five positions, V is selected only once over I or A, both of which have higher propensities for α-helix (PαV = 0.98, PαI = 1.09, PαA = 1.41). It is not fully understood why I has a greater propensity than V, but it has been suggested that the δ-carbon of L and I (absent in V) can increase propensity by burying nonpolar surface area against the helix (49), meaning that cores concomitantly improve helix propensity, further improving CC stability. L (PαL = 1.34), fixed for d position residues of AP-1, also contributes significantly to stability. Selection favoring higher propensity residues I and L, but not V, may reflect that our winner peptides are designed rather than native. This means that, although a designed inhibitor with the highest affinity possible is a top criterion, nature strives to evolve a balance between optimal and nonoptimal residues to suit the demands of the protein. No specific sequences are identified that conform to a speculated “trigger sequence” (50), although propensity may play a crude role during folding, possibly acting to enforce α-helical topology, thus ensuring structures are driven thermodynamically and on a biologically realistic time scale. FosW and JunW contain no central G residues that are replaced with higher propensity residues. Closely connected, but much harder to predict, is the role of context in determining stability, or how interactions of side chains with surrounding side chains affect overall propensity. In the future, it should be possible to factor in a greater negative design aspect where design for specificity, as well as stability, can play an increased role. More difficult will be designing to generate the lowest possible KD, while retaining specificity so that requirements of the proteins are met. All these considerations must be accounted for as well as being incorporated into library designs, to design coils that are both stable and specific. CC Prediction. We have rationalized our winning peptides based upon well understood principles. The algorithm of Fong et al. (24) falls noticeably short in predicting the Tm values for Fos–Fos homologues (Fig. 4 We have used a combination of simplistic core and electrostatic parameters, combined with well documented but little implemented (in CC stability prediction) helical propensity scales. In combining these parameters, we have devised a prediction algorithm. Although this has further potential for optimization, it is (at least in the context of bZIPs) on par with and certainly more simplistic than that of Fong et al. (24). A corollary of this work is to design more robust CC pairs and dominant negatives with improved therapeutic value, and as a potential use as building blocks in nanobiotechnological design. Materials and Methods Library Design and Cloning. Mega-primers were synthesized including relevant degenerate codons for residue options (for libraries), and a fill-in reaction was performed, resulting in 111-bp double-stranded oligonucleotides. These were cloned via NheI and AscI sites into a pQE16 derivative (Qiagen) containing a G/S linker tagged to fragment 1 (pAR200d; c-Jun and Jun library; ampicillin resistance; K.M.A., unpublished data) or fragment 2 (pAR300d; c-Fos and Fos library; chloramphenicol resistance; K.M.A., unpublished data) of murine dihydrofolate reductase (mDHFR), respectively. Library plasmids were transformed into BL21 gold cells (Stratagene) containing target plasmid and pREP4 (Qiagen; for lac repression). To assess library quality, we sequenced pools and single clones and found approximately equal distributions of varied amino acids. Pooled colonies exceeded the library size 5- to 10-fold. Selection of Winner Peptides. The protein-fragment complementation assay has been described (8, 9, 11). Briefly, CCs are tagged to either half of murine dihydrofolate reductase. Only two interacting helices will bring the two halves of the enzyme into close proximity, render the enzyme active, and result in colony formation on M9 minimal medium plates with trimethoprim (1 ng/ml) to inhibit bacterial dihydrofolate reductase. Surviving colonies were pooled, grown, and serially diluted under selective conditions. Fastest growth, and hence the highest-affinity interacting partner, will dominate the pool. Peptide Synthesis and Purification. Peptides (see supporting information for sequences) were synthesized by Protein Peptide Research and subsequently purified to >98% purity by using RP-HPLC with a Jupiter Proteo column (4-μm particle size, 90 Å pore size, 250 × 10 mm; Phenomenex) and a gradient of 5–50% acetonitrile (0.1% TFA) in 50 min at 1.5 ml/min. Correct masses were verified by electrospray mass spectrometry. Peptide concentrations were determined in water by using absorbance at 280 nm with an extinction coefficient of 1209 M−1·cm−1 (51) corresponding to a Tyr residue inserted into a solvent exposed b3 position. CD Measurements. Spectra and thermal melts were performed at 150 μM total peptide concentration in 10 mM K-phosphate/100 mM KF (pH 7) using a Jasco J-810 CD instrument. The temperature was ramped at a rate of 0.5°C per min. Melting profiles were ≥94% reversible with equilibrium denaturation curves fitted to a two-state model to yield the melting temperature (Tm)
Stability Prediction. Helix propensity (HP) is calculated as an average over the whole helix, i.e., the individual residues are summed and divided by the total number of residues. Electrostatics (ES) and core (C) are calculated by using a simple weighting scheme (see Results) and summed over the whole peptide to account for increased stability in longer helices. Scores for measured Tm values were fitted as follows
More detailed descriptions can be found in supporting information. Supporting Information
Acknowledgments This work was funded by the Emmy Noether program of the Deutsche Forschungsgemeinschaft (Grant Ar373). Footnotes Conflict of interest statement: No conflicts declared. This paper was submitted directly (Track II) to the PNAS office. References 1. Shaulian E., Karin M. Nat. Cell Biol. 2002;4:E131–E136. [PubMed] 2. Eferl R., Wagner E. F. Nat. Rev. Cancer. 2003;3:859–868. [PubMed] 3. Wolf E., Kim P. S., Berger B. Protein Sci. 1997;6:1179–1189. [PubMed] 4. Mason J. M., Müller K. M., Arndt K. M. Methods Mol. Biol. 2006 in press. 5. Woolfson D. N. Adv. Protein Chem. 2005;70:79–112. [PubMed] 6. Mason J. M., Arndt K. M. Chem. Biochem. 2004;5:170–176. 7. Lupas A. N., Gruber M. Adv. Protein Chem. 2005;70:37–78. [PubMed] 8. Pelletier J. N., Arndt K. M., Plückthun A., Michnick S. W. Nat. Biotechnol. 1999;17:683–690. [PubMed] 9. Arndt K. M., Pelletier J. N., Müller K. M., Alber T., Michnick S. W., Plückthun A. J. Mol. Biol. 2000;295:627–639. [PubMed] 10. O’Shea E. K., Lumb K. J., Kim P. S. Curr. Biol. 1993;3:658–667. [PubMed] 11. Arndt K. M., Pelletier J. N., Müller K. M., Plückthun A., Alber T. Structure (Cambridge, U.K.). 2002;10:1235–1248. 12. Harbury P. B., Zhang T., Kim P. S., Alber T. Science. 1993;262:1401–1407. [PubMed] 13. Zhu B. Y., Zhou N. E., Kay C. M., Hodges R. S. Protein Sci. 1993;2:383–394. [PubMed] 14. Bains N. P. S., Wilce J. A., Heuer K. H., Turnstall M., Mackay J. P., Bennet M. R., Weiss A. S., King G. F. Lett. Pept. Sci. 1997;4:67–77. 15. Gonzalez L., Jr, Woolfson D. N., Alber T. Nat. Struct. Biol. 1996;3:1011–1018. [PubMed] 16. Campbell K. M., Lumb K. J. Biochemistry. 2002;41:7169–7175. [PubMed] 17. Krylov D., Barchi J., Vinson C. J. Mol. Biol. 1998;279:959–972. [PubMed] 18. O’Shea E. K., Rutkowski R., Stafford W. F., III, Kim P. S. Science. 1989;245:646–648. [PubMed] 19. Schuermann M., Neuberg M., Hunter J. B., Jenuwein T., Ryseck R. P., Bravo R., Müller R. Cell. 1989;56:507–516. [PubMed] 20. Campbell K. M., Sholders A. J., Lumb K. J. Biochemistry. 2002;41:4866–4871. [PubMed] 21. Porte D., Oertel-Buchheit P., John M., Granger-Schnarr M., Schnarr M. Nucleic Acids Res. 1997;25:3026–3033. [PubMed] 22. John M., Briand J. P., Granger-Schnarr M., Schnarr M. J. Biol. Chem. 1994;269:16247–16253. [PubMed] 23. Acharya A., Ruvinov S. B., Gal J., Moll J. R., Vinson C. Biochemistry. 2002;41:14122–14131. [PubMed] 24. Fong J. H., Keating A. E., Singh M. Genome Biol. 2004;5:R11. [PubMed] 25. Dahiyat B. I., Gordon D. B., Mayo S. L. Protein Sci. 1997;6:1333–1337. [PubMed] 26. Williams R. W., Chang A., Juretic D., Loughran S. Biochim. Biophys. Acta. 1987;916:200–204. [PubMed] 27. Newman J. R., Keating A. E. Science. 2003;300:2097–2101. [PubMed] 28. Olive M., Krylov D., Echlin D. R., Gardner K., Taparowsky E., Vinson C. J. Biol. Chem. 1997;272:18586–18594. [PubMed] 29. Ludes-Meyers J. H., Liu Y., Munoz-Medellin D., Hilsenbeck S. G., Brown P. H. Oncogene. 2001;20:2771–2780. [PubMed] 30. Boysen R. I., Jong A. J., Wilce J. A., King G. F., Hearn M. T. J. Biol. Chem. 2002;277:23–31. [PubMed] 31. O’Shea E. K., Rutkowski R., Kim P. S. Cell. 1992;68:699–708. [PubMed] 32. Nakabeppu Y., Ryder K., Nathans D. Cell. 1988;55:907–915. [PubMed] 33. Zerial M., Toschi L., Ryseck R. P., Schuermann M., Muller R., Bravo R. EMBO J. 1989;8:805–813. [PubMed] 34. Cohen D. R., Ferreira P. C., Gentz R., Franza B. R., Jr, Curran T. Genes Dev. 1989;3:173–184. [PubMed] 35. Curran T., Van Beveren C., Verma I. M. Mol. Cell. Biol. 1985;5:167–172. [PubMed] 36. Suzuki T., Okuno H., Yoshida T., Endo T., Nishina H., Iba H. Nucleic Acids Res. 1991;19:5537–5542. [PubMed] 37. Berger B., Wilson D. B., Wolf E., Tonchev T., Milla M., Kim P. S. Proc. Natl. Acad. Sci. USA. 1995;92:8259–8263. [PubMed] 38. Betz S. F., Bryson J. W., DeGrado W. F. Curr. Opin. Struct. Biol. 1995;5:457–463. [PubMed] 39. Potekhin S. A., Medvedkin V. N., Kashparov I. A., Venyaminov S. Protein Eng. 1994;7:1097–1101. [PubMed] 40. Vinson C. R., Hai T., Boyd S. M. Genes Dev. 1993;7:1047–1058. [PubMed] 41. Woolfson D. N., Alber T. Protein Sci. 1995;4:1596–1607. [PubMed] 42. Gromiha M. M., Parry D. A. Biophys. Chem. 2004;111:95–103. [PubMed] 43. Chou P. Y., Fasman G. D. Biochemistry. 1974;13:211–222. [PubMed] 44. O’Neil K. T., DeGrado W. F. Science. 1990;250:646–651. [PubMed] 45. Chakrabartty A., Kortemme T., Baldwin R. L. Protein Sci. 1994;3:843–852. [PubMed] 46. Litowski J. R., Hodges R. S. J. Biol. Chem. 2002;277:37272–37279. [PubMed] 47. Doig A. J., Baldwin R. L. Protein Sci. 1995;4:1325–1336. [PubMed] 48. Pace C. N., Scholtz J. M. Biophys. J. 1998;75:422–427. [PubMed] 49. Chakrabartty A., Baldwin R. L. Adv. Protein Chem. 1995;46:141–176. [PubMed] 50. Kammerer R. A., Schulthess T., Landwehr R., Lustig A., Engel J., Aebi U., Steinmetz M. O. Proc. Natl. Acad. Sci. USA. 1998;95:13419–13424. [PubMed] 51. Du H., Fuh R. A., Li J., Corkan A., Lindsey J. S. Photochem. Photobiol. 1998;68:141–142. |
PubMed related articles
Your browsing activity is empty. Activity recording is turned off. |
|||||||||||||||
Nat Cell Biol. 2002 May; 4(5):E131-6.
[Nat Cell Biol. 2002]Nat Rev Cancer. 2003 Nov; 3(11):859-68.
[Nat Rev Cancer. 2003]Protein Sci. 1997 Jun; 6(6):1179-89.
[Protein Sci. 1997]Adv Protein Chem. 2005; 70():79-112.
[Adv Protein Chem. 2005]Adv Protein Chem. 2005; 70():37-78.
[Adv Protein Chem. 2005]Nat Biotechnol. 1999 Jul; 17(7):683-90.
[Nat Biotechnol. 1999]J Mol Biol. 2000 Jan 21; 295(3):627-39.
[J Mol Biol. 2000]Curr Biol. 1993 Oct 1; 3(10):658-67.
[Curr Biol. 1993]Science. 1993 Nov 26; 262(5138):1401-7.
[Science. 1993]Protein Sci. 1993 Mar; 2(3):383-94.
[Protein Sci. 1993]Nat Struct Biol. 1996 Dec; 3(12):1011-8.
[Nat Struct Biol. 1996]Biochemistry. 2002 Jun 4; 41(22):7169-75.
[Biochemistry. 2002]J Mol Biol. 1998 Jun 19; 279(4):959-72.
[J Mol Biol. 1998]Science. 1989 Aug 11; 245(4918):646-8.
[Science. 1989]Cell. 1989 Feb 10; 56(3):507-16.
[Cell. 1989]Biochemistry. 2002 Apr 16; 41(15):4866-71.
[Biochemistry. 2002]Nucleic Acids Res. 1997 Aug 1; 25(15):3026-33.
[Nucleic Acids Res. 1997]Science. 1993 Nov 26; 262(5138):1401-7.
[Science. 1993]J Mol Biol. 1998 Jun 19; 279(4):959-72.
[J Mol Biol. 1998]J Biol Chem. 1994 Jun 10; 269(23):16247-53.
[J Biol Chem. 1994]Biochemistry. 2002 Dec 3; 41(48):14122-31.
[Biochemistry. 2002]Science. 1993 Nov 26; 262(5138):1401-7.
[Science. 1993]J Mol Biol. 1998 Jun 19; 279(4):959-72.
[J Mol Biol. 1998]Genome Biol. 2004; 5(2):R11.
[Genome Biol. 2004]Protein Sci. 1997 Jun; 6(6):1333-7.
[Protein Sci. 1997]Biochim Biophys Acta. 1987 Nov 26; 916(2):200-4.
[Biochim Biophys Acta. 1987]J Mol Biol. 2000 Jan 21; 295(3):627-39.
[J Mol Biol. 2000]Genome Biol. 2004; 5(2):R11.
[Genome Biol. 2004]Science. 2003 Jun 27; 300(5628):2097-101.
[Science. 2003]Genome Biol. 2004; 5(2):R11.
[Genome Biol. 2004]J Biol Chem. 1997 Jul 25; 272(30):18586-94.
[J Biol Chem. 1997]Oncogene. 2001 May 17; 20(22):2771-80.
[Oncogene. 2001]J Biol Chem. 2002 Jan 4; 277(1):23-31.
[J Biol Chem. 2002]Cell. 1992 Feb 21; 68(4):699-708.
[Cell. 1992]J Biol Chem. 1997 Jul 25; 272(30):18586-94.
[J Biol Chem. 1997]Science. 2003 Jun 27; 300(5628):2097-101.
[Science. 2003]Cell. 1988 Dec 2; 55(5):907-15.
[Cell. 1988]Science. 2003 Jun 27; 300(5628):2097-101.
[Science. 2003]Proc Natl Acad Sci U S A. 1995 Aug 29; 92(18):8259-63.
[Proc Natl Acad Sci U S A. 1995]Science. 1989 Aug 11; 245(4918):646-8.
[Science. 1989]Science. 1993 Nov 26; 262(5138):1401-7.
[Science. 1993]Protein Sci. 1993 Mar; 2(3):383-94.
[Protein Sci. 1993]Curr Opin Struct Biol. 1995 Aug; 5(4):457-63.
[Curr Opin Struct Biol. 1995]Protein Eng. 1994 Sep; 7(9):1097-101.
[Protein Eng. 1994]Biochemistry. 2002 Dec 3; 41(48):14122-31.
[Biochemistry. 2002]Genes Dev. 1993 Jun; 7(6):1047-58.
[Genes Dev. 1993]Protein Sci. 1995 Aug; 4(8):1596-607.
[Protein Sci. 1995]Genes Dev. 1993 Jun; 7(6):1047-58.
[Genes Dev. 1993]Protein Sci. 1995 Aug; 4(8):1596-607.
[Protein Sci. 1995]J Mol Biol. 1998 Jun 19; 279(4):959-72.
[J Mol Biol. 1998]J Mol Biol. 1998 Jun 19; 279(4):959-72.
[J Mol Biol. 1998]Biochim Biophys Acta. 1987 Nov 26; 916(2):200-4.
[Biochim Biophys Acta. 1987]Biophys Chem. 2004 Oct 1; 111(2):95-103.
[Biophys Chem. 2004]Biochim Biophys Acta. 1987 Nov 26; 916(2):200-4.
[Biochim Biophys Acta. 1987]Biophys Chem. 2004 Oct 1; 111(2):95-103.
[Biophys Chem. 2004]Biochemistry. 1974 Jan 15; 13(2):211-22.
[Biochemistry. 1974]Science. 1990 Nov 2; 250(4981):646-51.
[Science. 1990]Protein Sci. 1994 May; 3(5):843-52.
[Protein Sci. 1994]Adv Protein Chem. 1995; 46():141-76.
[Adv Protein Chem. 1995]Proc Natl Acad Sci U S A. 1998 Nov 10; 95(23):13419-24.
[Proc Natl Acad Sci U S A. 1998]Genome Biol. 2004; 5(2):R11.
[Genome Biol. 2004]Genome Biol. 2004; 5(2):R11.
[Genome Biol. 2004]Nat Biotechnol. 1999 Jul; 17(7):683-90.
[Nat Biotechnol. 1999]J Mol Biol. 2000 Jan 21; 295(3):627-39.
[J Mol Biol. 2000]Genome Biol. 2004; 5(2):R11.
[Genome Biol. 2004]